A recent PricewaterhouseCoopers report estimated that the core diagnostic and therapeutic segment of the US personalised medicine market is worth $24bn. This figure is expected to nearly double by 2015, reaching $42bn. Peter Charlish investigates the rapidly emerging field of companion diagnostics
...
Please Login to read the full article.
